PE anti-mouse CD49b (pan-NK cells) Antibody
- 产品名称：
- PE anti-mouse CD49b (pan-NK cells) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 108907
- 产品应用：
- 108907
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- IL-2-propagated NK1.1+ cells from C57BL/6 mice
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen in vitro. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity2 and immunohistochemical staining5 of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections10. The binding of DX5 antibody to splenic NK cells can be blocked by HMa2 antibody.
- Application References
(PubMed link indicates BioLegend citation) -
- Arase H, et al. 2001. J. Immunol. 167:1141. (FC)
- Sepulveda H, et al. 1999. J. Immunol. 163:1133.
- Norian LA and Allen PM. 2004. J. Immunol. 173:835. (FC)
- Andoniou CE, et al. 2005. Nature Immunology 6:1011.
- Oertelt S, et al. 2006. J. Immunol. 177:1655. (IHC) PubMed
- Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370.
- Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
- Qui Q, et al. 2010. J. Immunol. 184:1681. (FC) PubMed
- Busche A, et al. 2011. J. Immunol. 186:2918. PubMed
- Kim HR, et al. 2011. Nephrology 16:545. (IHC) PubMed
- Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed
- Younos IH, et al. 2012. Int Immunopharmacol. 13:245. PubMed
- Honjo K, et al. 2012. PNAS. PubMed.
- Huang HN, et al. 2013. Biomaterials. 34:10151. PubMed
- Product Citations
-
- Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
- Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
- Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
- Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
- Nautiyal J, et al. 2013. Development. 140:1079. PubMed
- Lu H, et al. 2021. Autophagy. 17:2511. PubMed
- Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941. PubMed
- Sugimoto C, et al. 2022. Elife. 11:. PubMed
- Currier MA, et al. 2017. Oncotarget. 8:17412. PubMed
- Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
- Li J, et al. 2019. JCI Insight. 5. PubMed
- Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
- Steven A, et al. 2013. Mol Cancer Res. 11:1462. PubMed
- Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
- Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
- Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
- Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
- Vettorazzi S, et al. 2015. Nat Commun. 6: 7796. PubMed
- Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
- Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
- Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
- Sauma D, et al. 2017. Immunol Res. 10.1007/s12026-017-8936-9. PubMed
- Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
- Nakamura K, et al. 2013. Proc Natl Acad Sci U S A. 110:9421. PubMed
- Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
- Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
- Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
- Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
- Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
- Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
- Furuya Y, et al. 2013. Infect Immun . 81:3434. PubMed
- Brennd?rfer E, et al. 2014. J Immunol. 192:1671. PubMed
- Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
- Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
- Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
- Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
- Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
- Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
- Sinha S, et al. 2012. J Leukoc Biol. 92:713. PubMed
- Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
- Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
- Fan X, et al. 2014. PLoS One. 9:107638. PubMed
- RRID
- AB_313414 (BioLegend Cat. No. 108907) AB_313415 (BioLegend Cat. No. 108908)
- Structure
- Integrin α chain, 150 kD
- Distribution
-
NK cells, subset of T cells
- Function
- Adhesion
- Ligand/Receptor
- Collagen, laminin
- Cell Type
- NK cells, T cells
- Biology Area
- Cell Adhesion, Cell Biology, Immunology, Innate Immunity
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
-
1. Arase H, et al. 2001. J. Immunol. 167:1141.
2. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
3. Sasaki K, et al. 2003. Int. Immunol. 15:701.
4. Inoue O, et al. 2003. J. Cell Biol. 160:769.
- Gene ID
- 16398 View all products for this Gene ID
- UniProt
- View information about CD49b on UniProt.org
